Targeted Cancer Drugs Market Report 2025 (Global Edition)

Global Targeted Cancer Drugs Market Report 2025 Market Size Split by Type (Cancer Growth Blocker Drug, Monoclonal Antibody, Small Molecules, Immunotoxins, Others), by Indication (Lung Cancer, Stom...

Targeted Cancer Drugs Market Report Description

We have various report editions of Targeted Cancer Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Competitive Landscape: Targeted Cancer Drugs Market

In order to meet the increasing demands of consumers the industry players are now investing and giving more attention to their research and development of Targeted Cancer Drugs so that they sustain and survive in the competition. ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.

Recent Development     

In February 2024, AbbVie Inc. completed the acquisition of ImmunoGen, a biotechnology firm dedicated to creating antibody-drug conjugate therapies for cancer treatment, thereby enhancing its presence in the oncology sector. 
https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen 

In December 2023, AstraZeneca acquired Gracell, a worldwide clinical-stage biopharmaceutical company focused on pioneering cell therapies for cancer and autoimmune disorders, with the goal of bolstering cell therapy options for patients in these areas.
https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html
 

Top Companies Market Share in Targeted Cancer Drugs Industry: (In no particular order of Rank)

• Pfizer
• Incyte
• Novartis AG
• Eli Lilly
• Gilead
• Sanofi
• Galapagos
• AbbVie
• Vertex
• Teva
• Astellas Pharma
• Celgene
• Johnson & Johnson Private Limited
• Cipla Inc.
• Abbott
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which region dominate the Targeted Cancer Drugs market in 2024?

The expected sales of the North American Oncology Drugs market would top XX% by 2025. The revenue is expected to show a yearly growth rate of X%, therefore allowing a market volume of X% by 2031. North America is seeing an increasing need for precision treatments in cancer medicines. One of the chief causes of this rise is the increasing frequency of cancer in North America. As a result, there is an increasing need for effective cancer drugs to help in the management and treatment of the condition. Moreover, a shift toward personalized medicine is driving the development of specifically tailored treatments that could be adapted for each patient. The yearly count of diagnosed cancer cases is expected to hit nearly 3 million by 2040 based on information the American Association of Cancer Research provided in 2022.  North American oncology remedies industry is particularly energetic and cutthroat. Immunotherapies, which seek to improve the body's natural defense against cancer, are gaining acceptance. Furthermore gaining attention are combination treatments, which consist of the administration of many medications to fight against cancer. These changes are driving market creativity and easing the creation of patient-friendly cancer remedies. Furthermore, the new product approvals and launches in the region are expected to boost the market's growth. For instance, in March 2024, the United States FDA approved Janssen's Rybrevant (amivantamab) as a targeted therapy for treating adult patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Several elements are driving the rise of the cancer medication sector in North America. One important element is the aging group, which is driving up the incidence of cancer in the region. Furthermore, substantial funding for research and development helps to drive market innovation.
A strong regulatory structure helps to guarantee the safety and efficacy of fresh medicines. Underlying macroeconomic factors also influence the North American cancer therapy market. These elements take in healthcare spending, government rules, and reimbursement approaches. Furthermore, a rising trend toward value-driven healthcare is driving the development of drugs that produce better patient outcomes at lower costs. Along with technological, demographic, and economic forces, the oncology drug industry in North America is expected to continue growing over the future years.

Which region is expanding at the faster CAGR?

The market in Asia Pacific is expected to exhibit a rapid growth rate over the forecast period. This is due to the increasing awareness among the population. The growing prevalence of cancer and rising healthcare expenditure will favor market growth in the region. For instance according to Institute for health Economics, it shows that the number of cancer patients has been rising steadily over recent years along with the silver tsunami that is on the rise. Though recovery from cancer is becoming more common in wealthy countries, outcomes of therapy in middle-income areas are at best stagnant. It shows that most economies fall below the informal WHO public health expenditure standard of 5% of GDP. In some middle-income markets, excluding out-of-pocket costs, cancer accounts for only 1-2% of total health expenditures and for 5-9% in high-income markets.
 

The current report Scope analyzes Targeted Cancer Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Targeted Cancer Drugs Market Analysis

Based on type, monoclonal antibodies segment accounted for XX% of market share in 2024. Monoclonal antibodies are laboratory-engineered proteins that mimic the immune system's natural antibodies. These antibodies are produced by the body to assist the immune system in identifying pathogens, such as bacteria and viruses, and signaling them for elimination. Similar to the antibodies generated by the body, monoclonal antibodies are designed to target specific antigens. A significant number of monoclonal antibodies are utilized in cancer treatment as a form of targeted therapy, which means they are specifically crafted to engage with particular targets. Additionally, certain monoclonal antibodies function as immunotherapies by enhancing the immune system's ability to combat cancer. For instance, according to National Cancer Institute some monoclonal antibodies label cancer cells, thereby improving the immune system's capacity to identify and eradicate them. Rituximab serves as an example, as it attaches to the CD20 protein found on B cells and certain cancer cells, prompting the immune system to destroy these cells. B cells are a category of white blood cells. Other monoclonal antibodies facilitate the proximity of T cells to cancer cells, thereby aiding in the destruction of these malignant cells. An example of this is blinatumomab (Blincyto®), which binds to both CD19, a protein present on leukemia cells, and CD3, a protein located on T cells. This interaction enables T cells to approach leukemia cells closely enough to effectively respond and eliminate them.
Next-generation cell-penetrating antibodies have the potential to revolutionize cancer therapy, as detailed in the article "Advancements in Cell-Penetrating Monoclonal Antibody Treatment," published in Oncotarget's Volume 15 on November 22, 2024. This publication emphasizes notable progress in monoclonal antibody (mAb) treatments, particularly highlighting the 3E10 antibody, which was initially developed from studies on autoimmune mice with systemic lupus erythematosus. Unlike conventional mAbs that face challenges in accessing intracellular targets, this innovative cell-penetrating antibody effectively targets cancer cells by overcoming a significant limitation of existing therapies. By focusing on RAD51, a crucial intracellular protein involved in DNA repair, the 3E10 antibody demonstrates considerable potential for treating cancers characterized by impaired DNA repair mechanisms.

Anti-angiogenic medications are therapies designed to inhibit the formation of blood vessels by tumors. This intervention may decelerate cancer progression or, in certain instances, lead to tumor reduction. According to Cancer Research UK, Some of these drugs function by obstructing the vascular endothelial growth factor (VEGF) receptors, which are responsible for transmitting growth signals to the endothelial cells of blood vessels. These therapies are also referred to as cancer growth inhibitors or tyrosine kinase inhibitors (TKIs). Notable examples of TKIs that impede signaling within blood vessel cells include sunitinib, sorafenib, axitinib, regorafenib, cabozantinib, pazopanib, and lenvatinib. 
 

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Targeted Cancer Drugs Industry. Request a Free Sample PDF!

Based on indication, lung cancer segment accounted for XX% of market share in 2024. Lung carcinoma, another name for lung cancer, is a type of malignant tumor that starts in the lung. Genetic damage to the DNA of airway cells, frequently brought on by cigarette smoking or harmful chemical inhalation, is the cause of lung cancer. A tumor can arise as a result of damaged airway cells having the capacity to proliferate unchecked. Tumors spread throughout the lung and impair lung function if left untreated. Smoking is the leading cause of lung cancer, responsible for approximately 85% of all cases. One of the most prevalent and dangerous forms of cancer is lung cancer. In the United Kingdom, the illness affects around 43,000 people annually. With almost 2.48 million new cases and 1.8 million fatalities from the disease worldwide in 2022, lung cancer was the most common cancer diagnosed and the leading cause of cancer related deaths.

Breast cancer occurs when aberrant breast cells proliferate uncontrollably and develop into tumors. The tumors can grow throughout the body and become lethal if they are not treated. Breast cancer cells start inside the breast's milk ducts and/or milk-producing lobules. Early detection of the earliest form (in situ) is possible and poses little harm to life. It is possible for cancer cells to invade neighboring breast tissue. This results in tumors that thicken or produce lumps. Invasive tumors have the ability to metastasis, or spread, to other organs or surrounding lymph nodes Metastasis has the potential to be lethal. The course of treatment depends on the patient, the cancer type, and its extent. Medication, radiation theraphy, and surgery are all used in the treatment. For instance, according to World Health Organization in 2022, 2.3 million women received a breast cancer diagnosis, and 670,000 people died from the disease worldwide. Every nation in the world has breast cancer, which can strike women at any age after puberty but is more common in later life. 

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Targeted Cancer Drugs Route of Administration Segment Analysis

Based on route of administration, oral segment accounted for XX% of market share in 2024. Oral targeted therapies are becoming increasingly prevalent in the treatment of cancer. These therapies function by disrupting specific molecules or pathways that contribute to tumor growth. An example is the use of dabrafenib, a targeted BRAF inhibitor indicated for melanoma. Small-molecule inhibitors are administered orally, typically in the form of pills or capsules that can be easily swallowed. Similar to other forms of medication, oral anti-cancer drugs carry risks of toxicity and potential medication errors. Given that these medications are often dispensed in community settings, it is essential for patients, caregivers, family members, and all members of the multidisciplinary team to receive thorough education to ensure safe administration.
When a targeted therapy is prescribed in an oral format, the patient ingests the pill, capsule, or liquid just as they would with any other medication. Oral targeted therapies are generally taken at home, making it crucial for patients to understand the precise instructions regarding dosage and timing. If a physician has determined that oral chemotherapy is the most suitable treatment option, clear guidelines should be provided regarding the amount and schedule for taking the medication. 
According to American Cancer Society, adhering to the exact dosage and timing is vital to maintain consistent drug levels in the body, which is necessary for effectively targeting and eliminating cancer cells. Improper adherence to the treatment regimen can significantly impact its efficacy. While adjustments to the dosage may be necessary at times, such changes should only be made under the guidance of a physician. There is limited knowledge regarding the long-term effects of certain targeted therapies, which may necessitate special handling precautions. Nevertheless, many experts advise taking preventive measures as a precautionary step. Additionally, oral anti-cancer medications can be costly. Depending on the specific drug, some insurance plans may not fully cover the expenses, or may not provide coverage at all.
Monoclonal antibodies represent another class of targeted cancer therapies. these medications are administered parenterally since they are proteins and would be degraded in the gastrointestinal tract.

Monoclonal antibodies are typically delivered via a needle inserted into a blood vessel. Intravenous anti-cancer medications can be provided through a central venous access device (CVAD) or peripheral cannula. The method of administration may involve a bolus injection, intermittent, or continuous infusion based on the guidelines of the treatment protocol. Prior to initiating anti-cancer treatment, the patient’s requirements for venous access should be evaluated according to the treatment protocol's specifications, the patient's peripheral vasculature condition, history or risk of lymphoedema, and individual preferences. During all phases of anti-cancer drug administration, patients need to be monitored for any signs or symptoms indicative of hypersensitivity reactions. The most commonly utilized routes for parenteral delivery of cancer medications are intravenous and subcutaneous. Subcutaneous medications that are delivered subcutaneously are injected into the adipose tissue situated between the skin and muscle. Nursing practices may differ by facility, potentially limiting the volume of subcutaneous syringes to 2 to 2. 5 mL, necessitating multiple injection
sites for larger volumes. This guideline lacks evidence support, and some medications can be safely administered in larger doses. For instance, the rituximab monograph states that a 1400 mg dose of rituximab can be administered as a single injection of 11. 7 mL at one injection site. When compared to intramuscular or subcutaneous administration, larger fluid volumes are more easily tolerated with intravenous delivery. Vesicant or irritant medications that have the potential to harm tissues when administered intramuscularly or subcutaneously can be given intravenously.
 

• Oral
• Parenteral
• Others

Targeted Cancer Drugs Distribution Channel Segment Analysis

Based on distribution channel, hospital pharmacy segment accounted for XX% of market share in 2024. In relation to distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. The segment of hospital pharmacies is anticipated to lead the market. The rise in medication prescriptions at hospitals is attributed to the greater frequency of diagnoses occurring at these facilities.

Based on distribution channel, online pharmacy segment accounted for XX% of market share in 2024. The segment of online pharmacies is expected to grow with the largest market share due to its increasing popularity stemming from its simplicity and convenience. The growing access to the internet and the shift in preference of patients towards purchasing medications online attract e-commerce companies eager to invest in online healthcare platforms. For instance netmed provide 20% off on cancer drugs. As a result due to high cost of cancer drugs people tends to prefer online platform.
 

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion